Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.

The oncologist - 2 Jun 2023

Wang Xin, Beharry Andrea, Sheffield Brandon S, Cheema Parneet K

Abstract excerpt

INTRODUCTION: Cancer of unknown primary remains a challenging clinical entity. Despite receiving empiric chemotherapy, median overall survival is approximately 6-12 months. Site-specific therapy based on molecular characterization has been shown to improve outcomes; however, feasibility outside of clinical trials, especially in community centers, is lacking. This study explores the application of rapid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Feasibility Studies
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasms, Unknown Primary

Share to Point-of-Care Systems

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 36933203
DOI: 10.1093/oncolo/oyad054
PMCID: PMC10243757

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.PMID 36933203Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.Semantic proximity Read ↗

A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP)Semantic proximity Read ↗

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.Semantic proximity Read ↗

Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features.Semantic proximity Read ↗

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.Semantic proximity Read ↗

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read ↗

Real-world data analysis of patients with cancer of unknown primarySemantic proximity Read ↗

Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practiceSemantic proximity Read ↗

Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation featuresSemantic proximity Read ↗

Cancer of unknown primary (CUP) through the lens of precision oncology – a single institution perspectiveSemantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.